Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. by Houwelingen, K.P. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The version of the following full text has not yet been defined or was untraceable and may
differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/47907
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BMC Cancer OB io M e d  Central
Research article
Prevalence of von Hippel-Lindau gene mutations in sporadic renal 
cell carcinoma: results from the Netherlands cohort study
Kjeld P van Houwelingen^1, Boukje AC van Dijk*t2, Christina A Hulsbergen- 
van de Kaa3, Leo J Schouten2, Hanneke JM Gorissen1, Jack A Schalken1, 
Piet A van den Brandt2 and Egbert Oosterwijk1
Address: 'D epartm ent o f Urology, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, 2Departm ent of 
Epidemiology, NUTRIM, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands and 3D epartm ent o f Pathology, University 
Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands
Email: Kjeld P van Houwelingen - K.vanHouwelingen@ ncmls.kun.nl; Boukje AC van Dijk* - Boukje.vanDijk@ epid.unimaas.nl;
Christina A Hulsbergen-van de Kaa - C.Hulsbergen@ pathol.umcn.nl; Leo J Schouten - LJ.Schouten@ epid.unimaas.nl;
Hanneke JM Gorissen - H.Gorissen@ ncmls.kun.nl; Jack A Schalken - J.Schalken@ ncmls.kun.nl; Piet A van den 
Brandt - PA .vandenBrandt@ epid.unimaas.nl; Egbert Oosterwijk - E.Oosterwijk@ncmls.kun.nl
* Corresponding author tEqual contributors
Published: 02 June 2005 Received: 07 January 2005
BMC Cancer 2005, 5:57 d o i: l0 .l 186/1471-2407-5-57 A ccep ted: 02 June 2005
This article is available from: http://www.biom edcentra l.eom /l47l-2407/5/57 
©  2005 van Houwelingen et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons A ttribu tion  License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original w o rk  is properly cited.
Abstract
Background: Biallelic von Hippel-Lindau (VHL) gene defects, a rate-limiting event in the 
carcinogenesis, occur in approximately 75% o f sporadic clear-cell Renal Cell Carcinoma (RCC). 
W e studied the VHL mutation status in a large population-based case group.
M ethods: Cases were identified w ithin the Netherlands cohort study on diet and cancer, which 
includes 120,852 men and women. A fte r 11.3 years o f follow-up, 337 incident cases w ith 
histologically confirmed epithelial cancers were identified. D N A  was isolated from paraffin material 
collected from 51 pathology laboratories and revised by one pathologist, leaving material from  235 
cases. VHL mutational status was assessed by SSCP followed by direct sequencing, after testing 
SSCP as a screening too l in a subsample.
Results: The number o f mutations was significantly higher fo r clear-cell RCC compared to  other 
histological types. W e  observed 131 mutations in 114 out o f 187 patients (61%) w ith clear-cell 
RCC. The majority o f mutations were truncating mutations (47%). The mean tum or size was 72.7 
mm fo r mutated tum ors compared to  65.3 mm fo r wildtype tum ors (p = 0.06). N o statistically 
significant differences were observed fo r nuclear grade, TNM  distribution o r stage. In other 
histological types, we observed 8 mutations in 7 ou t o f 48 patients (15%), 1 mutation in 1 o f 6 
oncocytoma, 3 mutations in 2 o f 7 chromophobe RCC, 2 mutations in 2 o f 30 papillary RCC, no 
mutations in 1 collecting duct carcinoma and 2 mutations in 2 o f 4 unclassified RCC.
C onclusion: VHL mutations were detected in 61% o f sporadic clear-cell RCC. VHL mutated and 
wildtype clear-cell RCC did not differ w ith respect to  most parameters.
Open Access
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Background
Historically, the classification of Renal Cell Cancer (RCC) 
was based on morphological features. The majority of 
RCC are of the clear cell type (~80%); other subtypes are 
papillary RCC (10%), chromophobe RRC (5%), collect- 
ing-duct carcinoma (1%) and unclassified RCC (3-5%). 
Based on the work of numerous investigators, it became 
evident that RCC could be divided into genetically distinct 
classes: this resulted in the so-called Heidelberg classifica­
tion, which partly overlaps the former pathological classi­
fication of RCC based on morphological criteria. The 
most prominent common genetic aberration for clear-cell 
(conventional) RCC is loss of 3p. Characteristic for papil­
lary RCC is trisomy of chromosomes 3q, 7,8,12,16,17,20, 
and loss of the Y chromosome, and chromophobe RCC is 
characterized by a combination of loss of heterozygosity 
at chromosomes 1,2,6,10,13,17, and 21 [1].
Von Hippel-Lindau disease (VHL) is a rare inherited dis­
order associated with, amongst others, an enhanced risk 
for clear-cell RCC [2]. The VHL gene responsible for this 
syndrome was identified through linkage analyses and 
molecular cloning and is located on chromosome 3p25. 
After its identification it became evident that the VHL 
gene is also involved in the development of sporadic 
clear-cell RCC. Together with loss of the homologous 
chromosome 3p allele (3p LOH), VHL mutations are rate- 
limiting events in the carcinogenesis of clear-cell RCC 
[3,4]. Mutations have been observed in the entire gene 
and usually lead to a truncated inactive protein [5]. The 
VHL gene is considered a tumor suppressor gene, involved 
in cell cycle regulation, regulation of hypoxia inducible 
genes and proper fibronectin assembly in extracellular 
matrix [6,7]. It was estimated that approximately 75% of 
all sporadic clear-cell RCC harbor biallelic VHL defects 
[8]. In approximately 19% of sporadic clear-cell RCC, 
methylation of the VHL gene promoter appeared to be 
involved [9]. In approximately 10%-20% of sporadic 
clear-cell RCC no alteration in the VHL alleles was 
detected, indicating that other genes are involved in clear­
cell RCC carcinogenesis, possibly affecting the same sign­
aling pathway as VHL.
Several risk factors for developing RCC have been identi­
fied: tobacco smoking, obesity, drugs, such as phenacetin, 
hypertension and/or its medication, and occupational 
exposure to trichloroethylene, gasoline, petroleum prod­
ucts, asbestos, and iron processing fumes. The influence of 
dietary factors, such as vegetable, fruit vitamin C, caroten- 
oid, meat and milk product consumption, is controversial 
[10]. Multiple and specific types of VHL mutations in RCC 
have been associated with exposure to the industrial sol­
vent trichloroethylene [11,12]. Consumption of vegeta­
bles and citrus fruit decreased the frequency of VHL 
mutations among smokers and consumption of citrus
fruit decreased VHL mutation frequency for all patients 
[13]. These findings and investigations in animals [14] 
suggest that mutational patterns in the VHL gene may 
serve as an etiological imprint to factors causing renal can­
cer. Thus, it may be possible to improve our etiological 
insight in particular risk factors when a more specific end­
point than "RCC" can be defined, e.g. based on histology 
and mutational status of a gene involved in tumor 
carcinogenesis.
We decided to determine the mutational status of the VHL 
gene of RCC cases identified within a population-based 
cohort of 120,852 men and women aged 55-69 which 
was recruited in the Netherlands to study associations 
between dietary habits, lifestyle and cancer occurrence. To 
validate whether SSCP could serve as a prescreening 
method, SSCP and direct sequencing was evaluated in a 
subset of 20 patients. In this article we report on his- 
topathological and clinical parameters and the type and 
number of mutations in VHL observed in a large popula­
tion-based sample of cases.
Methods 
Study population
The RCC cases selected for this study were incident cases 
identified in the population of the Netherlands Cohort 
Study (NLCS) on diet and cancer. The NLCS has been 
described in detail elsewhere [15]. Briefly, this prospective 
study was initiated in 1986 and included 58,279 men and 
62,573 women, 55 to 69 years of age, who completed a 
self-administered questionnaire on diet, family history of 
cancer, and other risk factors for cancer at baseline. The 
entire cohort is being monitored for cancer occurrence by 
annual record linkage to the Netherlands Cancer Registry 
and to PALGA, a nationwide network and registry of 
histo- and cytopathology [16]. Information on sex and 
family history of RCC (at baseline) was retrieved from the 
NLCS database, while information on age at diagnosis 
and tumor localization was retrieved from the Nether­
lands Cancer Registry. Tumor stage was classified accord­
ing to the 1987 revision of the UICC-TNM classification 
[17], using information from the cancer registry and the 
pathology report. Tumor size was retrieved from the 
pathology report.
Tissue sample collection
Paraffin material was collected after approval by the Med­
ical Ethical Committees of Maastricht University, PALGA 
and the Netherlands cancer registry. From 1986 to 1997 
(11.3 years follow up) 355 kidney cancer cases (ICD-O-3: 
C64.9) were identified. Urothelial cell carcinomas were 
excluded and only histologically confirmed epithelial 
cancers were included (ICD-O: M8010-8119, 8140­
8570), leaving 337 cases. The PALGA database was also 
used to identify the location of tumor tissue storage in the
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Dutch pathology laboratories. For 273 cases, a PALGA 
record with information on the location of paraffin mate­
rial was available at the start of the collection of paraffin 
blocks. The tissue samples were distributed over 51 
pathology laboratories throughout the Netherlands.
For 251/273 cases (92%) paraffin blocks were collected. 
Failure to retrieve material was the result of the refusal of 
the pathology laboratory to cooperate (3 laboratories with 
material for 10 cases), the unavailability of suitable mate­
rial (i.e. only material from a biopsy, cytology or a metas­
tasis was present) (8 cases), not being able to locate the 
paraffin block at the laboratory (3 cases), and for 1 case 
the reason was not recorded. Paraffin blocks of parallel 
normal tissue were collected if available. Collected archi­
val tissue sample blocks were registered and coded using 
a unique identification number.
Revision
Genomic DNA was extracted from five 20-|im slices from 
each tumor and normal specimen. A flanking section was 
haematoxylin and eosin (HE) stained for histological pur­
poses, e.g. grading and estimation of percentage of tumor 
cells. One experienced pathologist (CAHK) reviewed all 
HE stained slides. The RCC were classified according to 
the World Health Organization (WHO) classification of 
Tumours of 2002 [18]. Nuclear grading was performed 
according to Fuhrman [19]. Grading was based on the 
most atypical focus in the paraffin block used for DNA 
extraction, with a dimension of at least one high power 
field.
Material of 16 cases was discarded after revision. The col­
lected material was unsuitable for analysis, because it con­
Table 1: Primers used to amplify the VHL gene
cerned a biopsy (N = 2) or a metastasis (N = 2) or no 
tumor tissue was present (N = 4) or material contained 
less than 10% malignant cells (N = 7) (tumor samples had 
to contain at least 10% malignant cells to decrease the 
possibility of ignoring mutations). Material from one case 
was reclassified as urothelial cell carcinoma and subse­
quently excluded. As a result, tumor DNA from 235 cases 
was available for further analysis.
DNA isolation
Genomic DNA was prepared as follows: paraffin was 
removed with xylene and genomic DNA was extracted by 
salt-precipitation. Briefly, 450 |il of cell lysis solution (10 
mM Tris/HCl (pH 7.4), 400 mM NaCl, 2 mM EDTA), 25 
|il of 10% SDS and 50 |il of proteinase K solution (20 mg/ 
ml) were added to the tissue samples and incubated over­
night at 55°C. Proteins were precipitated using 175 |il of 
saturated NaCl, followed by centrifugation (2 minutes, 
13.200 rpm). DNA was precipitated by the addition of 0.6 
volumes of iso-propanol, dissolved in TE (pH 7.4) and 
stored at -20°C. The DNA concentration and purity was 
measured at 260 and 280 nm.
V H L  mutation analysis
PCR primers used for amplification are described in Table
1. Amplification of DNA for SSCP analysis and sequence 
analysis was performed as follows: 100 ng of the extracted 
DNA was subjected to 35 cycles of PCR: 40 sec at 92°C, 40 
sec at Tm and 40 sec at 72°C. Exon amplification was per­
formed in 30 |il of buffer: 50 mM KCl, 10 mM Tris-HCl 
(pH 9.0), 1.5 mM MgCl2, 1% triton X-100, 0.1% (w/v) 
gelatin, 250 uM dNTP's, 25 pmol of each primer and 1U 
Taq polymerase (HT Biotechnology Ltd.). For SSCP anal­
ysis, 0.2 |il of [a 32P] dATP (10 mCi/ml, ~3000 Ci/mmol,
Name Sequence 5'>3' Exon Tm Fragment length
Sense3a G G T CTG G A T CGC G G A  GGG A l 64°C * 19 1 bp
Asense4a GC C  CGG C C T C C A  T C T  C C T l
Sense5a A G T  CGG GCG CCG AG G  A G T l 64°C * 184 bp
Asense6a CCG TCG  A AG  TTG  A G C  C A T A C l
Sense7a C C C  A G G  T C A  T C T  T C T  G C A  A T l 64°C f l59  bp
Asense8a CTG CTG G G T CGG GCC T A A  G l
Sense9 GTG G C T C TT T A A  C A A  C C T TTG  C 2 60°C£ l94  bp
Asensel0 C C T G T A  C TT A C C  A C A  A C A  A C C  T T A  TC 2
S ense lla C A C  T G A  G G A  T T T  G G T T T T  TG C 3 55°C l62  bp
Asensel2a TC C  A G G  T C T  TT C  TG C  A C A  T T T 3
Sensel3a GAC  A T C  G TC  AG G  TC G  C TC  T A 3 55°C l50  bp
Asensel4a T C A  A A A  G C T GAG A TG  A A A  CAG TG 3
*  3% DMSO added fo r PCR 
f  1.5% DMSO and 2.5 mM MgCl2 added fo r PCR
i  4% DMSO and 1.0 mM MgCl2 added fo r PCR
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FIRMA) was added.
For SSCP analyses, 5 |il of the radiolabeled PCR product 
was diluted in 5 |il loading buffer (96% formamide, 20 
mM EDTA, 0.05% brom ophenol blue and xylene cyanol), 
boiled for 3 min, and quenched on ice before loading. 
Three |il of each sample was loaded on a 0.5x MDE gel, 
containing 0.6x TBE either with or without 10% (v/v) 
glycerol. Electrophoresis was performed at room temper­
ature at 5W for MDE gels without glycerol, and at 7W for 
MDE gels with 10% (v/v) glycerol, using 0.6x TBE as elec­
trophoresis buffer. After 20 hours of electrophoresis, the 
gels were transferred to W hatmann 3 MM paper (FIRMA) 
and dried on a gel dryer. The separated fragments were vis­
ualized by Hyperfilm-MP (FIRMA) exposure.
For sequence analysis, the PCR products were purified 
using the Wizard™ PCR preps purification system 
(Promega Corp.). Sequencing was performed at the local 
central sequence facility using BigDye Terminator and the 
ABI basecaller (Applied Biosystems). Mutations were 
identified by visual inspection of sequences provided by 
the ABI basecaller, and called when unequivocally present 
on the sense and/or antisense strand, and when the area 
under the curve of peaks changed by more than 5%, com­
pared to the area under the curve of the normal signal.
Feasibility and comparability pilot
Twenty samples were analyzed by PCR-SSCP and direct 
sequencing to investigate the suitability of PCR-SSCP as a 
screening tool preceding direct sequencing. After evalua­
tion, we decided to use PCR-SSCP as a screening instru­
m ent before direct sequencing. All remaining samples 
were subjected to PCR-SSCP, which was only followed by 
direct sequencing in case of an aberrant band pattern on 
the PCR-SSCP. Samples were also sequenced when equiv­
ocal PCR-SSCP results were obtained.
Statistical analyses
The overall frequency of VHL mutations as well as the type 
of m utation and affected exon and codon were computed 
for all 235 cases. Differences between histological sub­
types were assessed by the %2-test. For clear-cell RCC, 
mutated and wildtype tumors were compared with respect 
to age at diagnosis, sex, grade, TNM classification [17], 
stage and family history of RCC. Differences in mean val­
ues of age at diagnosis as a continuous variable were eval­
uated by the student's t-test. Differences in the categorical 
variables sex, family history of RCC, grade, TNM classifi­
cation and stage were evaluated for significance by the %2- 
test. A p-value of 0.05 or less was considered statistically 
significant. Statistical analyses were performed with the 
STATA statistical software package (STATA statistical soft­
ware, Release 7, STATA corporation, College Station, TX, 
USA, 2001).
T a b le  2: M u ta t io n  analysis in  20 sam p les b y  SSCP and d ire c t  
sequenc ing
D irec t sequencing
Positive Negative
Primerset 3/4
SSCP Positive 0 S
Negative
Primerset S/6
0 IS
SSCP Positive 2 0
Negative
Primerset 7/8
0 I8
SSCP Positive 4 2
Negative 
Primerset 9 /I0
0 I4
SSCP Positive 3 0
Negative 
Primerset I I / I 2
0 I7
SSCP Positive 4 I
Negative 
Primerset I 3 / I4
0 IS
SSCP Positive 2 0
Negative 0 I8
Positive on SSCP means: indication o f a m utation o r  no t assessable 
after tw o  attempts.
Positive on d irect sequencing means: p roo f o f a mutation.
Results
PCR-SSCP as a screening tool preceding direct sequencing
To evaluate whether PCR-SSCP could be used to distin­
guish between wildtype and mutated VHL, we determined 
the VHL status of 20 cases by SSCP and direct sequencing 
(Table 2). SSCP and direct sequencing were mostly in 
agreement. In all cases where disparate results were 
obtained, this concerned aberrant signals in PCR-SSCP, 
followed by a negative result by direct sequencing (Table 
2). Most importantly, we never found a m utation in the 
sequence analysis after a negative PCR-SSCP (0% false- 
negatives) (Table 2). However, we are aware that the 
sampling size is limited, and it is known that SSCP as a 
screening tool is neither 100% sensitive nor specific. 
Therefore, we estimated the chance of a positive result on 
direct sequencing after a negative result on the SSCP (i.e., 
the chance that a m utation will be missed by using SSCP 
as a screening instrument). The point estimate for the per­
centage of false-negatives based on SSCP is 0%, with an 
upper confidence limit between 3.7% and 16.9%, based 
either on the individual analyses (N = 97), or on the 
number of cases (N = 20) (see Additional file 1: Calcula­
tion of the estimated upper 95% confidence limit). Differ­
ent types of mutations were identified by SSCP followed 
by direct sequencing in this pilot.
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V H L  mutations and clinical parameters
We were able to analyze at least one tum or block for 235 
patients with 236 tumors (one patient had two primary 
tumors). After revision by CAHK, the analyzed samples 
could be subdivided as follows: clear-cell RCC (188/236, 
79.7%), papillary RCC (30/236, 12.7%); chromophobe 
RCC (7/236, 3.0%); oncocytoma (6/236, 2.5%), collect­
ing duct carcinoma (1/236, 0.4%), and unclassified RCC 
(4/236, 1.7%). For 198 cases one paraffin block was ana­
lyzed, while for 34 cases 2 paraffin blocks were analyzed 
and for 3 cases 3 paraffin blocks were analyzed. In 10 
cases, a different genotype was observed in  different 
tum or blocks obtained from 1 tumor. In 6 cases, 1 sample 
contained wildtype VHL while the other sample harbored 
one or more mutations. For the statistical analyses these 
cases were analyzed as "mutated". In 13 cases, 2 m uta­
tions in  the same paraffin block were observed. In one 
patient with two primary tumors, both tumors showed a 
different mutation. In total we observed 253 outcomes 
(139 mutations (in 121 patients) and 114 wildtype) for 
235 patients with 236 primary tumors. All 139 observed 
mutations are described. (see Additional file 2: Descrip­
tion of observed mutations (N = 139), histological param­
eters and personal characteristics for 121 cases).
VHL gene mutations were mostly observed in  clear-cell 
RCC, but also in unclassified RCC (2/4); papillary RCC 
(2/30); chromophobe RCC (3 mutations in 2/7 patients) 
and oncocytoma (1/6) (see Additional file 2: Description 
of observed mutations (N = 139), histological parameters 
and personal characteristics for 121 cases). The percentage 
of patients with a m utation was significantly higher for 
clear-cell tumors compared to tumors of other histologi­
cal types (x2: 32.9; p-value<0.001). In the remainder of 
this paper, we will only consider clear-cell RCC, leaving 
204 outcomes (131 mutations (in 114 patients) and 73 
wildtype) for 187 patients with 188 primary tumors. Nine 
outcomes were mutations in intronic sequences, possibly 
affecting splicing. The majority of observed mutations in 
coding regions lead to a truncated VHL product 
(insertion/deletion mutations leading to a frameshift and 
nonsense mutations, 62/122) or to a deleted/inserted or 
altered amino acid, 47/122). The percentage of point 
mutations was much higher in exon 1 (50.7%) than in 
exon 2 and 3 (29.6 and 23.1, respectively).
Figure 1 shows the type of m utation plotted against the 
codon number. We observed 62 truncating mutations, 
which consisted of 4 nonsense mutations and 58 dele­
tions or insertions leading to a shift of the reading frame 
(Figure 1A), 15 insertions or deletions that did not affect 
the reading frame (Figure 1B), 32 missense mutations 
(Figure 1C) and 13 silent mutations (Figure 1D).
Cases with a m utation were older (mean: 67.8 years; sd: 
4.7) than cases without a m utation (mean: 67.1; sd: 4.6). 
The mean age difference at diagnosis was 0.8 years with a 
95% CI ranging from -0.6 through 2.2 years. The percent­
age of m en with clear-cell RCC with a VHL m utation was 
somewhat higher than the percentage of males among 
patients with a clear-cell RCC without a VHL mutation, 
63.2 % vs. 53.4% (x2: 1.75; p-value: 0.19).
The mean tum or size was 72.7 mm for tumors with a VHL 
mutation compared to 65.3 mm for tumors without a 
VHL mutation. The difference was 7.3 mm with a 95% CI 
from -2.1 m m  through 16.8 mm. Other tum or parameters 
for patients with a primary clear-cell RCC with or without 
a VHL m utation are shown in Table 3. We did not observe 
a difference in nuclear grade, T, N, M, or stage between 
m utated and wildtype tumors.
For 3 patients, a positive family history was reported; 2 of 
these patients (Sample id's: 1003 and 306/1600) had a 
clear-cell tum or harboring a mutation. One patient with a 
papillary tum or reported a positive family history; no 
mutations in  the VHL gene were observed in  the corre­
sponding tum or sample. Obviously, these numbers are 
too small to engage in  statistical testing.
Discussion
The von Hippel-Lindau (VHL) gene is a tum or suppressor 
gene predisposing to both sporadic clear-cell (conven­
tional) RCC and von Hippel-Lindau disease. We analyzed 
235 cases of primary sporadic RCC, of which 187 cases 
presented with the histological subtype clear-cell RCC, 
identified within the Netherlands cohort study on diet 
and cancer. VHL mutations were assessed by PCR-SSCP, 
followed by direct sequencing when aberrant signals were 
detected in SSCP. Screening by SSCP was considered 
appropriate, since we never detected a m utation by direct 
sequencing after a negative result on the SSCP in a pilot 
study. Furthermore, we estimated the upper 95% confi­
dence limit for cases missed at 3.7% or 16.9%, based on 
the individual analyses (N = 97) or on the number of cases 
(N = 20). Therefore, mutated cases may have been over­
looked, which placed them in the wildtype group. This 
would have resulted in  a reduction of contrast between 
wildtype and mutated groups.
We observed 131 mutations in 114 out of 187 patients 
(61%) in patients with clear-cell tumors. Estimates 
reported in the literature [2,20-30] range from 36% [25] 
to 54% [27], and therefore our estimate appears high. 
However, our estimate is close to the estimate of 75% as 
discussed in the review by Cohen [8]. This difference in 
the observed proportion of mutations in  the VHL gene 
may be attributed to the use of different techniques, e.g., 
SSCP vs. direct sequencing, to contamination with normal
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Figure 1
Type of m utation  p lo tted  against th e  codon num ber. A. Truncating mutations (Frameshift & Nonsense mutations) B. 
In-frame insertions/deletions C. Missense mutations D. Silent mutations Codon l - l l 4  encodes exon l, codon l l 4 - l 5 5  
encode exon 2, and codon 155-2l3 encode exon 3.
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T a b le  3: T u m o r  p a ra m e te rs  fo r  p a tie n ts  w ith  a c le a r-ce ll tu m o r ,  also s tra t if ie d  by  V H L  m u ta t io n  s ta tu s
A ll tum ors (N  = 18 V H L mutated tum ors (N  = 115) W ild type  tum ors (N  = 73)
N % N % N % X2 p-value f
T  (T N M *) 
1 5 2.7 4 3.5 1 1.4
2 93 49.5 55 47.8 38 52.1
3A 35 18.6 20 17.4 15 20.6
3B 50 26.6 34 29.6 16 21.9
4 2 1.1 1 0.9 1 1.4 0.18§** 0.67
X 3 1.6 1 0.9 2 2.7
N (TN M *) 
0 126 67.0 78 67.8 48 65.8
1 7 3.7 6 5.2 1 1.4
2 7 3.7 5 4.4 2 2.7 1.51^** 0.22
X 48 25.5 26 22.6 22 30.1
M (TN M *) 
0 131 69.7 77 67.0 54 74.0
1 26 13.8 18 15.7 8 1 1.0 0.99** 0.32
X 31 16.5 20 17.4 1 1 15.1
Stage (T N M *) 
1 5 2.7 4 3.5 1 1.4
2 83 44.2 46 40.0 37 50.7
3 66 35.1 42 36.5 24 32.9
4 32 17.0 22 19.1 10 13.7 l.4 l§ * * 0.24
X 2 1.1 1 0.9 1 1.4
Nuclear grading f£  
I 46 24.5 27 23.5 19 26.0
II 67 35.6 43 37.4 24 32.9
III 48 25.5 29 25.2 19 26.0
IV 27 14.4 16 13.9 11 15.1 0.43 0.94
*  Based on pathological TN M  unless unknown, then clinical TN M  (U ICC, 1987) was used [17] 
f  Based on the review  by one experienced pathologist (C A H K)
£ According to  Fuhrman [19]
§1-2 vs. 3 -4  
f l l - 2  vs. 0
* *  Excludes "X  (unknown) " category
tissue components, or to the type of material analyzed 
(fresh or archival paraffin material). In our study, we used 
SSCP followed by direct sequencing, as most investiga­
tions did [2,20-29]. To avoid ignoring VHL mutations 
through contamination with normal tissue, samples 
needed to contain at least 10% tumor cells. The vast 
majority of samples (180 out of 190) contained at least 
50% viable tum or tissue. The sample with the lowest per­
centage of viable tumor tissue, in which we observed a 
mutation, contained 30% of viable tum or tissue. For 2 
samples the percentage of viable tumor tissue was lower 
(10% and 20%), thus we cannot formally exclude the pos­
sibility that we overlooked an existing mutation. We iden­
tified cases in a population-based study after 11.3 years of 
follow-up; the time span and the num ber of patients and 
hospitals involved excluded the possibility to collect fresh
material. Three other studies on sporadic RCC used paraf­
fin embedded material and the percentages of mutations 
detected were 46% [29], 50% [22] and 54% [27].
The occurrence of various types of mutations is compara­
ble to other studies of this size [21,24,26,27], but some 
differences are also apparent. The presence of silent m uta­
tions is not commonly reported; only Ma et al. [27] 
reported 13% of silent mutations, similar to 11% 
observed by us. It is possible that others do not report 
silent mutations because the investigators do no t wish to 
designate these as true mutations since their relevance is 
unclear. The percentage of frameshift mutations was 
approximately 50% in most studies [21,26], comparable 
to the 48% observed in the current study. The percentage 
of in-frame deletions/insertions was higher in our study
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(12%) as compared to the percentage in other studies 
(<5%) [21,26]. Compared to the distribution of m utation 
data present in the Universal VHL Mutation database with 
747 mutations [31], the relative am ount of point m uta­
tions is much higher in the database (64%), compared to 
the percentage of point mutations we observed (44%), as 
well as the frequency of nonsense mutations (11% vs. 
3%). However, many of the mutations in the Mutation 
database concern germline mutations identified in VHL- 
families. It has been suggested that the mutational spec­
trum between germline and sporadic VHL mutations may 
differ [25], which could explain the disparity. We were not 
able to select records for sporadic tumors in  the database, 
but Gallou et al. [26] described mutations for 145 spo­
radic cases from this database. Compared to our results, 
the percentage of nonsense mutations was higher (8% vs. 
3%) and the percentage of in-frame deletions or inser­
tions was lower (4% vs. 12%) [26].
Furthermore, we searched the Universal VHL Mutation 
database [31] for the mutations observed in the cases with 
a positive family history of RCC. The T>A (silent) m uta­
tion at codon 139 (sample id 1003) was not reported 
before, the deletion of 1 nucleotide at codon 146 (sample 
id 306) was recorded in the database twice, while the sec­
ond 1 nucleotide deletion at codon 167 (sample id 1600) 
had not been reported before.
For 10 RCC cases, we observed different VHL genotypes in 
different tum or samples obtained from one tumor. Sam­
ples were re-analyzed to exclude technical errors. Again, 
different VHL genotypes, identical to the earlier geno­
types, were observed, showing that tum or heterogeneity 
appears to play a role. This was an unexpected finding in 
view of the general acceptance that a m utation in the VHL 
gene is an early event in  clear-cell RCC carcinogenesis, 
because one would then expect monogenetic VHL expres­
sion. Nevertheless, it is possible that genetic instability 
leads to additional mutational events, eventually leading 
to different VHL genotypes in  clear-cell RCC. This was 
underscored by 13 cases showing 2 mutations within the 
same paraffin block and other studies have also reported 
multiple mutations per primary tum or [21,27,29].
The distribution of histological subtypes was comparable 
to the distribution described before [[32], p2692]. Sur­
prisingly, we also found VHL mutations in  some of the 
non-clear-cell RCC samples that were collected. These 
results are in  contrast with the current opinion that VHL 
mutations are exclusively restricted to clear-cell RCC. VHL 
mutations, however, have also been reported in  chromo­
phobe RCC, although these were clustered in the 5'UTR/ 
promoter region [22], and Brauch et al. [12] described a 
renal oncocytoma with a VHL mutation. To our knowl­
edge, others have not yet described VHL mutations in  pap­
illary RCC. It is conceivable that genetic instability 
following tumor-initiating events leads to VHL mutations 
acquired at a later stage of tum or development. As 
expected, the relative occurrence of VHL mutations in the 
non-clear-cell RCC renal tumors was much lower than in 
clear-cell RCC, emphasizing the crucial role of VHL m uta­
tions in clear-cell RCC carcinogenesis.
The high percentage of mutations observed, the observa­
tion of mutational heterogeneity (different genotypes in 1 
or different samples from the same tumor), and the obser­
vation of mutations in other histological types, raises the 
question whether paraffin material is suitable for analysis. 
It has been shown, however, that VHL gene mutations can 
be detected in archival paraffin material [33]. Identical 
mutations were observed in exon 2 in 3 cases for which 
archival paraffin material and tumor derived cell lines 
were assessed by SSCP and sequencing [33]. On the other 
hand, it has also been reported that artifacts may occur 
when archival paraffin material is used [34]. Williams et 
al. reported up to 1 m utation artifact per 500 bases 
recorded. The chance of such artificial mutations in for­
malin-fixed material was inversely correlated with the 
num ber of cells used in the PCR: the fewer the cells, the 
more artifacts. No artifacts were observed when 300 cells 
were used and only 1 artifact was observed in 150 cells 
(0.03%). The highest frequency of artifacts was observed 
when using 10 or 20 cells, and equaled 0.2 % [34]. The 
num ber of cells in our analyses, however, was large (>500 
cells), since 5 20-|im slices of paraffin embedded material 
were used and biopsies were excluded.
The mean tum or size was larger for mutated tumors than 
for wildtype tumors, however no t statistically significant. 
Two other studies did no t show a difference in tum or size
[24.28]. VHL gene mutations leading to reduced or inac­
tive VHL protein (pVHL) could theoretically lead to a 
larger tum or size. In the absence of pVHL, hypoxia induc­
ible factor becomes stabilized and upregulates a myriad of 
hypoxia-inducible genes, resulting in hypervascular 
tumors [35]. This should be a growth advantage. Our 
results and results from others [24,28] showed no associ­
ation with nuclear grade (according to Fuhrman) [19]. It 
was difficult to compare TNM and stage, since different 
classifications were used in different studies and the TNM 
classification has changed definitions in recent years. We 
reviewed all cases and classified them according to the 
1987 version of the TNM classification [17]. We did not 
observe a difference in T, N, M, or stage between mutated 
and wildtype tumors, as was confirmed by 2 other studies
[24.28]. One study, however, reported a higher percentage 
of mutations in pT3 tumors with a VHL m utation or 
hypermethylation, compared to tumors without VHL 
alteration (64% vs. 40%) [21].
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Phenotype should also be considered. Mutations may 
impair pVHL function. However, in order for pVHL to 
lose its function, biallelic VHL defects have to occur. We 
did not measure LOH, since it is well documented that 
LOH commonly occurs in RCC cases, with estimates rang­
ing from 74% [30] to 93% [21]. Kondo et al. showed 97% 
LOH in mutated or hypermethylated samples compared 
to 81% LOH in wildtype samples [24]. Furthermore, 
silent mutations do not lead to an altered protein, but 
these types of mutations were not common (13/131) in 
our study. Also, pVHL formation may be inhibited by epi­
genetic silencing, which has been reported to occur in 
19% of clear-cell RCC [9]. This could have resulted in mis- 
classification in  comparing pathological parameters, 
because samples with epigenetic silencing only were clas­
sified as wildtype tumors, as we were no t able to investi­
gate epigenetic silencing in  the current study. Finally, cells 
in  cell culture have been shown to produce two types of 
proteins: pVHL30 and pVHL19 (a results of internal trans­
lation from the second m ethionine within the VHL open 
reading frame (Met 54) [36-38]. The pVHL19 product has 
been shown to inhibit the production of hypoxia-induci- 
ble genes, bu t does not bind to fibronectin [36,37]. 
Reintroduction of pVHL19 has been shown to inhibit 
tum or formation in nude mice [37]. We detected m uta­
tions 5' of codon 54 in 11 cases; these are unusual and 
would be predicted to affect pVHL30, bu t no t pVHL19 
translation products. However in  5 of these 11 cases, a 
second m utation was observed 3 'of codon 54. So, in 5 of 
these cases the other m utation may be relevant. For the 
other 6 cases, these mutations may not lead to a function­
ally inactive protein, and thus we may have misclassified 
these. However, as remarked before, the pVHL19 variant 
does not bind to fibronectin and thus may not contribute 
to the maintenance of the extracellular matrix.
Conclusion
VHL mutations were observed in  61% of sporadic clear­
cell RCC. No differences were observed in nuclear grade, 
TNM distribution or stage between VHL mutated and 
wildtype clear-cell RCC. However, the tum or size was 
larger for VHL mutated clear-cell RCC. This study forms a 
good basis to study possible associations between poten­
tial risk factors and VHL mutations in  clear-cell RCC. Ulti­
mately, this should lead to greater insight in  the etiology 
of clear-cell RCC.
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